Pemetrexed in advanced non-small-cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 8, 2010, Pages 1387-1402

  Fuld, Alexander D ^a   Dragnev, Konstantin H ^a   Rigas, James R ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Antimetabolite; First line therapy; Non small cell lung cancer; Pemetrexed; Second line therapy

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPTERIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYTOTOXIC AGENT; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IBUPROFEN; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; KIDNEY DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEOPLASM; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHARMACOLOGICAL PARAMETERS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77952119805     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.482560     Document Type: Review

References (92)

1. Garcia M, Jemal A, Ward E, et al. Global Cancer Facts & Figures 2007. Available from: http://www.cancer.org/ downloads/STT/ Global-Facts-and-Figures- 2007-rev2. pdf [Last accessed March 2010]
2. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-249
3. Horner M, Ries L, Krapcho M, Neyman N, editors. SEER Cancer Statistics Review, 1975-2006. Available from: http:// seer.cancer.gov/csr/1975-2006/ [Last accessed 7 November 2009]
4. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients. Chest 2005;128:452-462
5. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-4625
6. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage i.v. non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266
7. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98
8. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291
9. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Jf Clin Oncol 2003;21:3016-3024
10. Noble J, Ellis PM, Mackay JA, et al. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2006;1:1042-1058
11. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-808
12. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-1380
13. Bailey LB, Gregory JF III. Folate metabolism and requirements. J Nutr 1999;129:779-782
14. Saif MW, Chu E. Antimetabolites. In: DeVita VT Jr, Rosenberg AE, Lawrence TS, editors. Cancer: Principles & Practice of Oncology, 8th edition. Philadelphia: Lippincott, Williams & Wilkins, 2008. p. 427-436
15. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-417
16. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-793
17. Calvert AH, Walling JM. Clinical studies with MTA. Brit J Cancer 1998;78(Suppl 3):35-40
18. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d] pyrimidinebased antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123
19. Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999;26:42-47
20. Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999;19:437-443
21. Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 2009;69:5467-5474
22. Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363-373
23. Rinaldi DA, Burris HA, Dorr FA, et al. Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13:2842-2850
24. McDonald AC, Vasey PA, Adams L, et al. A Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 1998;4:605-610
25. Rinaldi DA, Kuhn JG, Burris HA, et al. A Phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-380
26. Nakagawa K, Kudoh S, Matsui K, et al. A Phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Brit J Cancer 2006;95:677-682
27. Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007;13:2675-2683
28. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194-1199
29. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter Phase II trial. Ann Oncol 2000;11:435-440
30. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001;92:595-600
31. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737-741
32. Smit EF, Mattson K, von Pawel J, et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a Phase II study. Ann Oncol 2003;14:455-460
33. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-552
34. Scagliotti GV, Shin D-M, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561
35. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644
36. Sweeney CJ, Takimoto CH, Latz JE, et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin Cancer Res 2006;12:536-542
37. Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552-562
38. Shvartsbeyn M, Edelman MJ. Pemetrexed-induced typhlitis in non-small cell lung cancer. J Thorac Oncol 2008;3:1188-1190
39. Cripps C, Burnell M, Jolivet J, et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999;10:1175-1179
40. Hanna N, Shepherd FA, Fossella FV, et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597
41. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103
42. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized Phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-4411
43. Bearz A, Garassino I, Cavina R, et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 2008;60:240-245
44. Lee H-Y, Ahn M-J, Park YH, et al. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. Lung Cancer 2009;66:338-343
45. Ohe Y, Ichinose Y, Nakagawa K, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206-4212
46. Cullen MH, Zatloukal P, Sorenson S, et al. A randomized Phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008;19:939-945
47. Smit EF, Burgers SA, Biesma B, et al. Randomized Phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-2045
48. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005;104:2449-2456
49. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, Phase II trial. Clin Cancer Res 2005;11:690-696
50. Stathopoulos GP, Dimitroulis J, Toubis M, et al. Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a Phase I-II trial. Lung Cancer 2007;57:66-71
51. Clarke SJ, Boyer MJ, Millward M, et al. A Phase I/II study of pemetrexed and vinorelbine in patients with non-smallcell lung cancer. Lung Cancer 2005;49:401-412
52. Monnerat C, Le Chevalier T, Kelly K, et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2004;10:5439-5446
53. Ma CX, Nair S, Thomas S, et al. Randomized Phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5929-5937
54. Treat J, Bonomi P, McCleod M, et al. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a Phase II trial. Lung Cancer 2006;53:77-83
55. West HL, Wakelee HA, Perry MC, et al. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a Phase II clinical trial. Ann Oncol 2009;20:850-856
56. Gridelli C, Kaukel E, Gregorc V, et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, Phase II trial. J Thorac Oncol 2007;2:221-229
57. Dudek AZ, Larson T, McCleod MJ, et al. Phase I/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol 2008;3:394-399
58. Blakely LJ, Schwartzberg L, Keaton M, et al. A Phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009;66:97-102
59. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551
60. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-3224
61. Tiseo M, Bartolotti M, Gelsomino F, Ardizzoni A. First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Rev Anticancer 2009;9:425-435
62. Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it matter? Oncology 2009;23:1133-1140
63. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a Phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). EJC Suppl 2007;5:363-364
64. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-263
65. Lurje G, Manegold PC, Ning Y, et al. Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther 2009;8:1000-1007
66. Nakagawa T, Otake Y, Yanagihara K, et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer 2004;43:145-149
67. Nakagawa T, Tanaka F, Otake Y, et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002;35:165-170
68. Shintani Y, Ohta M, Hirabayashi H, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003;104:790-795
69. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596
70. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-118
71. Schiller JH, Ramalingam SS. Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be better after all. J Clin Oncol 2009;27:3265-3267
72. Grossi F, Aita M, Follador A, et al. Sequential, alternating, and maintenance/ consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007;12:451-464
73. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-3283
74. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study. Lancet 2009;374:1432-1440
75. US Food and Drug Adminstration Center for Drug Evaluation and Research. Alimta. Available from: http:// www.accessdata.fda.gov/drugsatfda-docs/ label/2009/021462s018s021s022lbl.pdf [Last accessed November 2009]
76. European Medicines Agency. Summary of Product Characteristics. Alimta. Available from: http://www.emea.europa. eu/humandocs/Humans/EPAR/alimta/ alimta.htm [Last accessed November 2009]
77. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG Study N0426. J Clin Oncol 2009.23.6406
78. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-3289
79. A Phase II trial of carboplatin, bevacizumab and pemetrexed in advanced non-small cell lung cancer Available from: http://clinicaltrials.gov/ ct2/show/NCT00614822 [Last accessed January 2010]
80. Pemetrexed plus bevacizumab in pretreated, advanced or metastatic non small cell lung cancer (NSCLC). Available from: http://clinicaltrials.gov/ ct2/show/NCT00741221 [Last accessed January 2010]
81. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study design for the pointbreak study: a randomized, open-label Phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/ bevacizumab versus paclitaxel/ carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252-256
82. A study of tarceva (erlotinib) and standard of care chemotherapy in patients with advanced, recurrent, or metastatic non-small cell lung cancer. Available from: http://clinicaltrials.gov/ ct2/show/NCT00556322 [Last accessed November 2009]
83. Trial of pemetrexed versus erlotinib in pretreated patients with non small cell lung cancer (NSCLC). Available from: http://clinicaltrials.gov/ct2/ show/ NCT00440414 [Last accessed November 2009]
84. A Phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment in patients with nonsquamous NSCLC. Available from: http:// clinicaltrials.gov/ct2/show/NCT00447057 [Last accessed January 2010]
85. Stinchcombe TE, West HL. Maintenance therapy in non-small-cell lung cancer. Lancet 2009;374:1398-1400
86. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598
87. A study of induction and maintenance treatment of advanced non-squamous non small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/ NCT00789373 [Last accessed November 2009]
88. Study of patients with advanced non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/ NCT00948675 [Last accessed January 2010]
89. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study. Lancet 2009;374:1432-1440
90. Kubota K, Niho S, Enatsu S, et al. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase ii study. J Thorac Oncol 2009;4(12):1530-1536
91. Trial of poor performance status patients (ToPPS). Available from: http:// clinicaltrials.gov/ct2/show/NCT00892710 [Last accessed March 2010]
92. Pemetrexed, carboplatin, and bevacizumab as first-line therapy in treating older patients with stage IIIB or stage IV non-small cell lung cancer. Available from: http://clinicaltrials.gov/ ct2/show/NCT00798603 [Last accessed March 2010]